Earlier preclinical studies suggested that repeated systemic resiquimod exposure may lead to TLR tolerance and impaired anti-tumor responses as typified by significantly reduced systemic cytokine release and hyporesponsiveness in TLR7-expressing myeloid cells [49]. The gene discussed is TLR7; the disease is neoplasm.